{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T15:31:30Z","timestamp":1781710290821,"version":"3.54.5"},"reference-count":62,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005375","name":"Latvijas Zin\u0101tnes Padome","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005375","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cervical cancer incidence and mortality in Latvia is one of the highest in Europe, but data on HR-HPV prevalence in cervical disease are lacking. We aimed to investigate HR-HPV prevalence in cervical squamous cell carcinoma (CSCC) and cervical dysplasia (CD), association with disease severity, and prevalence changes over time.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials &amp;amp; Methods<\/jats:title>\n                    <jats:p>Cervical tissue samples from 145 patients were retrieved and used for HR-HPV genotyping using two commercially available PCR kits.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Only six CD samples were HR-HPV negative (6\/66, 9.1%), while all CSCC were positive. Over 50% samples (75\/139) harbored one, 33.8% two, 10.1% three, and 2.2% four HR-HPV genotypes. CSCC was more likely to harbor multiple HR-HPVs (p=0.0280). HPV16 remained most prevalent in CSCC and CD and was followed by HPV33 (32\/139, 23.0%), HPV39 (13\/139, 9.4%), and HPV18 (11\/139, 7.9%). CSCC samples were more likely to have high HR-HPV loads (p=0.025). Disease severity expressed as CINI to CSCC grade 3, correlated with HR-HPVs detected (p=0.015, r=0.202) and HPV16 and HPV39 loads (p&amp;lt;0.001, r=0.354; p&amp;lt;0.001, r=0.307). prevalence decreased, insignificantly across the analyzed period, while HPV18 decreased significantly (2016-18: 17.4% vs. 2022-24: 2.2%;\u00a0p=0.032). HPV66, 45, 39, 31, and 33 (2016-18: 13%; 2022-24:31.1%; p=0.045) increased.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>HPV16 remained the most prevalent HR-HPV, while HPV18 decreased. Other HR-HPV genotypes (HPV 66\/45\/39\/31\/33) demonstrated an increase in prevalence. Cervical disease severity was linked to specific HR-HPV loads and the number infecting HR-HPVs. These findings highlight the need for extended HR-HPV genotyping with determination of viral load, and request more epidemiological studies analyzing historical and current samples.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2025.1676334","type":"journal-article","created":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T05:34:45Z","timestamp":1770183285000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Persistently high prevalence of HPV16 and rising prevalence of non-16\/18 HR-HPV genotypes in cervical precancer and cancer in Latvia in 2016-2024 shape the severity of cervical disease"],"prefix":"10.3389","volume":"15","author":[{"given":"Liba","family":"Sokolovska","sequence":"first","affiliation":[{"name":"Institute of Microbiology and Virology, Riga Stradins University","place":["Riga, Latvia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karina","family":"Biserova","sequence":"additional","affiliation":[{"name":"Institute of Microbiology and Virology, Riga Stradins University","place":["Riga, Latvia"]},{"name":"Pathology Institute, Pauls Stradins Clinical University Hospital","place":["Riga, Latvia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arta","family":"Spridzane","sequence":"additional","affiliation":[{"name":"Institute of Microbiology and Virology, Riga Stradins University","place":["Riga, Latvia"]},{"name":"Oncology Centre of Latvia, Riga East Clinical University Hospital","place":["Riga, Latvia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daira","family":"Krisane","sequence":"additional","affiliation":[{"name":"Pathology Institute, Pauls Stradins Clinical University Hospital","place":["Riga, Latvia"]},{"name":"Pathology Centre, Riga East Clinical University Hospital","place":["Riga, Latvia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alesja","family":"Dudorova","sequence":"additional","affiliation":[{"name":"Institute of Microbiology and Virology, Riga Stradins University","place":["Riga, Latvia"]},{"name":"Pathology Institute, Pauls Stradins Clinical University Hospital","place":["Riga, Latvia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svetlana","family":"Gebrila","sequence":"additional","affiliation":[{"name":"Institute of Microbiology and Virology, Riga Stradins University","place":["Riga, Latvia"]},{"name":"Pathology Institute, Pauls Stradins Clinical University Hospital","place":["Riga, Latvia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilvija","family":"Krasovska","sequence":"additional","affiliation":[{"name":"Oncology Centre of Latvia, Riga East Clinical University Hospital","place":["Riga, Latvia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dmitry","family":"Perminov","sequence":"additional","affiliation":[{"name":"E. Gulbis Laboratory Ltd","place":["Riga, Latvia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrise","family":"Orlova","sequence":"additional","affiliation":[{"name":"Centrala Laboratorija Ltd","place":["Riga, Latvia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Petrovska","sequence":"additional","affiliation":[{"name":"Centrala Laboratorija Ltd","place":["Riga, Latvia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juris","family":"Jansons","sequence":"additional","affiliation":[{"name":"Institute of Microbiology and Virology, Riga Stradins University","place":["Riga, Latvia"]},{"name":"Latvian Biomedical Research and Study Center","place":["Riga, Latvia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Androniks","family":"Mitildzans","sequence":"additional","affiliation":[{"name":"Institute of Microbiology and Virology, Riga Stradins University","place":["Riga, Latvia"]},{"name":"Oncology Centre of Latvia, Riga East Clinical University Hospital","place":["Riga, Latvia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jurijs","family":"Nazarovs","sequence":"additional","affiliation":[{"name":"Pathology Institute, Pauls Stradins Clinical University Hospital","place":["Riga, Latvia"]},{"name":"Pathology Centre, Riga East Clinical University Hospital","place":["Riga, Latvia"]},{"name":"Department of Pathology, Riga Stradins University","place":["Riga, Latvia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Isaguliants","sequence":"additional","affiliation":[{"name":"Institute of Microbiology and Virology, Riga Stradins University","place":["Riga, Latvia"]},{"name":"Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet","place":["Stockholm, Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,4]]},"reference":[{"key":"B1","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2019.12.013","article-title":"Effect of organised cervical cancer screening on cervical cancer mortality in Europe: a systematic review","volume":"127","author":"Jansen","year":"2020","journal-title":"Eur J Cancer"},{"key":"B2","article-title":"Global burden of cervical cancer: current estimates, temporal trend and future projections based on the GLOBOCAN 2022","volume":"5","author":"Wu","year":"2025","journal-title":"J Natl Cancer Cent"},{"key":"B3","volume-title":"EU country cancer profile: Latvia 2025","year":"2025"},{"key":"B4","doi-asserted-by":"crossref","DOI":"10.1093\/eurpub\/ckae075","article-title":"Understanding the high-risk human papillomavirus prevalence and associated factors in the European country with a high incidence of cervical cancer","volume":"34","author":"Berza","year":"2024","journal-title":"Eur J Public Health"},{"key":"B5","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jiaa032","article-title":"Human papillomavirus genotype replacement: still too early to tell","volume":"224","author":"Man","year":"2021","journal-title":"J Infect Dis"},{"key":"B6","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.3390\/v16081245","article-title":"Update on effects of the prophylactic HPV vaccines on HPV type prevalence and cervical pathology","volume":"16","author":"Hampson","year":"2024","journal-title":"Viruses"},{"key":"B7","doi-asserted-by":"crossref","first-page":"633162","DOI":"10.3389\/fcimb.2021.633162","article-title":"Genotype distribution change after human papillomavirus vaccination in two autonomous communities in Spain","volume":"11","author":"Freire-Salinas","year":"2021","journal-title":"Front Cell Infect Microbiol"},{"key":"B8","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.21893","article-title":"Incidence and types of human papillomavirus infections in adolescent girls and young women immunized with the human papillomavirus vaccine","volume":"4","author":"Schlecht","year":"2021","journal-title":"JAMA Netw Open"},{"key":"B9","doi-asserted-by":"crossref","DOI":"10.1007\/s00404-020-05879-7","article-title":"Human papilloma virus (HPV) prevalence upon HPV vaccination in Swedish youth: a review based on our findings 2008-2018, and perspectives on cancer prevention","volume":"303","author":"Du","year":"2021","journal-title":"Arch Gynecol Obstet"},{"key":"B10","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.1017\/S0950268823000122","article-title":"Ability of epidemiological studies to monitor HPV post-vaccination dynamics: a simulation study","volume":"151","author":"Bonneault","year":"2023","journal-title":"Epidemiol Infect"},{"key":"B11","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(14)70841-2","article-title":"Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study","volume":"14","author":"Tabrizi","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"B12","doi-asserted-by":"crossref","first-page":"2497608","DOI":"10.1080\/21645515.2025.2497608","article-title":"Impact of human papillomavirus vaccines in the reduction of infection, precursor lesions, and cervical cancer: A systematic literature review","volume":"21","author":"Harper","year":"2025","journal-title":"Hum Vaccines Immunother"},{"key":"B13","article-title":"Inform\u0101cija par cilv\u0113ka papilomas v\u012brusu","year":""},{"key":"B14","unstructured":"ICD-10 version\n          \n          \n          2019"},{"key":"B15","doi-asserted-by":"crossref","first-page":"34","DOI":"10.5858\/arpa.2018-0259-RA","article-title":"Cervical adenocarcinomas: A heterogeneous group of tumors with variable etiologies and clinical outcomes","volume":"143","author":"Hodgson","year":"2019","journal-title":"Arch Pathol Lab Med"},{"key":"B16","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13027-025-00682-y","article-title":"New mouse model based on adenocarcinoma 4T1 cells expressing HPV16 E6 and E7 applied to assess the efficacy of therapeutic and prophylactic E6\/E7-based HPV16 vaccines","volume":"20","author":"Jansons","year":"2025","journal-title":"Infect Agent Cancer"},{"key":"B17","first-page":"3998","article-title":"Polymerase chain reaction: basic protocol plus troubleshooting and optimization strategies","volume":"63","author":"Lorenz","year":"2012","journal-title":"J Vis Exp JoVE"},{"key":"B18","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.01176-18","article-title":"Clinical and analytical evaluation of the anyplex II HPV HR detection assay within the VALGENT-3 framework","volume":"56","author":"O\u0161trbenk","year":"2018","journal-title":"J Clin Microbiol"},{"key":"B19","doi-asserted-by":"crossref","first-page":"105638","DOI":"10.1016\/j.jcv.2023.105638","article-title":"Allplex HPV HR Detection assay fulfils all clinical performance and reproducibility validation requirements for primary cervical cancer screening","volume":"170","author":"O\u0161trbenk Valen\u010dak","year":"2024","journal-title":"J Clin Virol"},{"key":"B20","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.29649","article-title":"Comparative evaluation of Anyplex II HPV28 and Allplex HPV28 molecular assays for human papillomavirus detection and genotyping in anogenital cancer screening","volume":"96","author":"Naegele","year":"2024","journal-title":"J Med Virol"},{"key":"B21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0320978","article-title":"Comparative evaluation of Allplex HPV28 and Anyplex II HPV28 assays for high-risk HPV genotyping in cervical samples","volume":"20","author":"Mafi","year":"2025","journal-title":"PloS One"},{"key":"B22","doi-asserted-by":"crossref","DOI":"10.1016\/j.ygyno.2004.01.044","article-title":"A population-based study of cervical carcinoma and HPV infection in Latvia","volume":"93","author":"Silins","year":"2004","journal-title":"Gynecol Oncol"},{"key":"B23","first-page":"1","article-title":"The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds","volume":"18","author":"C Kitchener","year":"2014","journal-title":"Health Technol Assess Winch Engl"},{"key":"B24","doi-asserted-by":"crossref","DOI":"10.1002\/ijc.29085","article-title":"Long-term HPV type-specific risks of high-grade cervical intraepithelial lesions: a 14-year follow-up of a randomized primary HPV screening trial","volume":"136","author":"Smelov","year":"2015","journal-title":"Int J Cancer"},{"key":"B25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/LGT.0000000000000494","article-title":"Clinical utility of human papillomavirus genotyping in cervical cancer screening: A systematic review","volume":"24","author":"Bonde","year":"2019","journal-title":"J Low Genit Tract Dis"},{"key":"B26","unstructured":"WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1584677\/full","article-title":"Prevalence\u00a0of human papillomavirus genotypes in Latvia among women participating in cervical cancer screening","volume":"15","author":"Stasulane","year":"2025","journal-title":"Front Oncol"},{"key":"B28","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.1961","article-title":"Human papillomavirus types in cervical high-grade lesions or cancer among Nordic women\u2014Potential for prevention","volume":"8","author":"Dovey de la Cour","year":"2019","journal-title":"Cancer Med"},{"key":"B29","doi-asserted-by":"crossref","DOI":"10.1038\/sj.bjc.6604324","article-title":"Prevalence of type-specific HPV infection by age and grade of cervical cytology: data from the ARTISTIC trial","volume":"98","author":"Sargent","year":"2008","journal-title":"Br J Cancer"},{"key":"B30","doi-asserted-by":"crossref","DOI":"10.1016\/j.ygyno.2019.05.024","article-title":"Age-specific HPV type distribution in high-grade cervical disease in screened and unvaccinated women","volume":"154","author":"Aro","year":"2019","journal-title":"Gynecol Oncol"},{"key":"B31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0272205","article-title":"Distribution of human papillomavirus genotypes by severity of cervical lesions in HPV screened positive women from the ESTAMPA study in Latin America","volume":"17","author":"Correa","year":"2022","journal-title":"PloS One"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2019.30.e52","article-title":"Human papillomavirus genotype-specific risk in cervical carcinogenesis","volume":"30","author":"So","year":"2019","journal-title":"J Gynecol Oncol"},{"key":"B33","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.24169","article-title":"Prevalence of human papillomavirus genotypes and relative risk of cervical cancer in China: a systematic review and meta-analysis","volume":"9","author":"Xu","year":"2018","journal-title":"Oncotarget"},{"key":"B34","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djg037","article-title":"Human papillomavirus infection and time to progression and regression of cervical intraepithelial neoplasia","volume":"95","author":"Schlecht","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"B35","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/1471-2334-9-119","article-title":"Epidemiologic natural history and clinical management of Human Papillomavirus (HPV) Disease: a critical and systematic review of the literature in the development of an HPV dynamic transmission model","volume":"9","author":"Insinga","year":"2009","journal-title":"BMC Infect Dis"},{"key":"B36","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/cea59317-929c-464a-b3f7-e095248f229a","article-title":"Natural history of progression of HPV infection to cervical lesion or clearance: analysis of the control arm of the large, randomised PATRICIA study","volume":"8","author":"Jaisamrarn","year":"2013","journal-title":"PloS One"},{"key":"B37","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1002\/ijc.29971","article-title":"Progression of HPV infection to detectable cervical lesions or clearance in adult women: Analysis of the control arm of the VIVIANE study","volume":"138","author":"Skinner","year":"2016","journal-title":"Int J Cancer"},{"key":"B38","doi-asserted-by":"crossref","DOI":"10.1080\/14760584.2022.2021077","article-title":"Progression from human papillomavirus (HPV) infection to cervical lesion or clearance in women (18\u201325 years): Natural history study in the control arm subjects of AS04-HPV-16\/18 vaccine efficacy study in China between 2008 and 2016","volume":"21","author":"Welby","year":"2022","journal-title":"Expert Rev Vaccines"},{"key":"B39","doi-asserted-by":"crossref","first-page":"100293","DOI":"10.1016\/j.eclinm.2020.100293","article-title":"A study of type-specific HPV natural history and implications for contemporary cervical cancer screening programs","volume":"22","author":"Demarco","year":"2020","journal-title":"EClinicalMedicine"},{"key":"B40","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1177\/10668969221134692","article-title":"Could HPV type 33 be more risky than we thought","volume":"31","author":"Purut","year":"2023","journal-title":"Int J Surg Pathol"},{"key":"B41","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/2045-3701-2-17","article-title":"Human papillomavirus type 58: the unique role in cervical cancers in East Asia","volume":"2","author":"Chan","year":"2012","journal-title":"Cell Biosci"},{"key":"B42","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0107573","article-title":"Meta-analysis on prevalence and attribution of human papillomavirus types 52 and 58 in cervical neoplasia worldwide","volume":"9","author":"Chan","year":"2014","journal-title":"PloS One"},{"key":"B43","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01285-17","article-title":"Ancient evolution and dispersion of human papillomavirus 58 variants","volume":"91","author":"Chen","year":"2017","journal-title":"J Virol"},{"key":"B44","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.29262","article-title":"Genetic variability analysis of human papillomavirus 58: Novel sublineage identification and persistent infection association","volume":"95","author":"Wang","year":"2023","journal-title":"J Med Virol"},{"key":"B45","first-page":"45","article-title":"High-risk and multiple human papillomavirus infections associated with cervical abnormalities in Japanese women","volume":"10","author":"Sasagawa","year":"2001","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"B46","doi-asserted-by":"crossref","DOI":"10.1158\/1055-9965.EPI-06-0129","article-title":"Human papillomavirus infections with multiple types and risk of cervical neoplasia","volume":"15","author":"Trottier","year":"2006","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"B47","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jiq139","article-title":"Human papillomavirus infection with multiple types: pattern of coinfection and risk of cervical disease","volume":"203","author":"Chaturvedi","year":"2011","journal-title":"J Infect Dis"},{"key":"B48","article-title":"Multiple HPV genotype infection impact on invasive cervical cancer presentation and survival","volume":"12","author":"Genta","year":"2017","journal-title":"PloS One"},{"key":"B49","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.3390\/v13071342","article-title":"Multiple human papilloma virus (HPV) infections are associated with HSIL and persistent HPV infection status in korean patients","volume":"13","author":"Kim","year":"2021","journal-title":"Viruses"},{"key":"B50","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1186\/s12879-023-08634-w","article-title":"Epidemiologic characteristics of high-risk HPV and the correlation between multiple infections and cervical lesions","volume":"23","author":"Luo","year":"2023","journal-title":"BMC Infect Dis"},{"key":"B51","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.29835","article-title":"Distribution and diagnostic value of single and multiple high-risk HPV infections in detection of cervical intraepithelial neoplasia: A retrospective multicenter study in China","volume":"96","author":"Ye","year":"2024","journal-title":"J Med Virol"},{"key":"B52","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.24666","article-title":"Findings of multiple HPV genotypes in cervical carcinoma are associated with poor cancer-specific survival in a Swedish cohort of cervical cancer primarily treated with radiotherapy","volume":"9","author":"Kaliff","year":"2018","journal-title":"Oncotarget"},{"key":"B53","doi-asserted-by":"crossref","DOI":"10.1002\/ijgo.12117","article-title":"Awareness of HPV infection and attitudes toward HPV vaccination among Latvian adolescents","volume":"137","author":"Patel","year":"2017","journal-title":"Int J Gynaecol Obstet Off Organ Int Fed Gynaecol Obstet"},{"key":"B54","article-title":"Barriers and motivators for uptake of cervical cancer prevention strategies in Eastern Europe: the perspective from Latvia","volume":"28","author":"Patel","year":"2019","journal-title":"Acta Dermatovenerol Alp Pannonica Adriat"},{"key":"B55","unstructured":"European commission\n          \n          \n          \n          2022"},{"key":"B56","doi-asserted-by":"crossref","first-page":"976","DOI":"10.3389\/fonc.2019.00976","article-title":"Evaluation of cervical intraepithelial neoplasia occurrence following the recorded onset of persistent high-risk human papillomavirus infection: A retrospective study on infection duration","volume":"9","author":"Lazare","year":"2019","journal-title":"Front Oncol"},{"key":"B57","unstructured":"Global HPV prevention policy atlas"},{"key":"B58","first-page":"660","article-title":"An\u00a0overview of cervical cancer epidemiology and prevention in the Baltic States","volume":"23","author":"Kojalo","year":"2023","journal-title":"BMC\u00a0Public Health"},{"key":"B59","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s12885-021-09126-3","article-title":"Roles of extended human papillomavirus genotyping and multiple infections in early detection of cervical precancer and cancer and HPV vaccination","volume":"22","author":"Song","year":"2022","journal-title":"BMC Cancer"},{"key":"B60","doi-asserted-by":"crossref","first-page":"7976","DOI":"10.1038\/s41598-024-57085-z","article-title":"Characterization of human papillomavirus genotypes and their coverage in vaccine delivered to Ethiopian women","volume":"14","author":"Abate","year":"2024","journal-title":"Sci Rep"},{"key":"B61","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1186\/s12985-024-02496-7","article-title":"High prevalence of HPV-56 and HPV-39 in Sari, Iran: an analysis of genotype distribution","volume":"21","author":"Letafati","year":"2024","journal-title":"Virol J"},{"key":"B62","unstructured":""}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1676334\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T05:34:57Z","timestamp":1770183297000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1676334\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,4]]},"references-count":62,"alternative-id":["10.3389\/fonc.2025.1676334"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1676334","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,4]]},"article-number":"1676334"}}